Expression and clinical predictive value of CHST6 in glioma patients
10.3969/j.issn.1002-0152.2023.09.002
- VernacularTitle:胶质瘤中碳水化合物磺基转移酶6的表达与临床预测价值
- Author:
Beichuan ZHAO
1
,
2
;
Ruoheng XUAN
;
Guitao YANG
;
Gengqiang LING
;
Zhibo XIA
Author Information
1. 中山大学附属第一医院神经外科(广州 510080)
2. 中山大学附属第七医院神经医学中心
- Keywords:
Glioma;
Carbohydrate sulfotransferase 6;
Bioinformatics;
Prediction model;
Biomarker
- From:
Chinese Journal of Nervous and Mental Diseases
2023;49(9):519-526
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between carbohydrate sulfotransferase 6(CHST6)expression level and prognosis in glioma patients and construct prognosis model by using bioinformatics method.Methods To analyze the difference of CHST6 expression in glioma.The median CHST6 expression was divided into high and low expression groups.The prognostic differences between the groups were analyzed.The expression level of CHST6 and different clinical features were analyzed by Cox regression,and the prediction and improvement model was established,and the validity improvement was compared with the control model.Results A total of 1204 medical records were included in TCGA and CGGA databases.CHST6 was significantly up-regulated in glioma samples(TCGA vs.GTEx,Z= 2.457,P＜0.001;CGGA vs.GTEx,Z=4.800,P＜0.001),and was an independent prognostic factor for glioma together with age,WHO grade,IDH mutation status,and 1p19q co-deletion(Cox analysis β=0.02,SE=0.01,HR=1.02,95%CI:1.01～1.04,P=0.01;C-Index 0.885,95%CI:0.862～0.908),has higher predictive validity than the control model(Improved model vs.Control model:TCGA d=0.036±0.004,SE=0.002,P=0.007;CGGA d=0.087±0.004,SE=0.002,P=0.001).Conclusion The high expression of CHST6 may be a predictor of poor prognosis and abnormal immune function in glioma patients.
